Avidity Biosciences Files Q1 2025 10-Q Report
| Field | Detail |
|---|---|
| Company | Avidity Biosciences, Inc. |
| Form Type | 10-Q |
| Filed Date | May 8, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, quarterly-report, pharmaceuticals
TL;DR
Avidity Bio Q1 2025 10-Q filed. Check financials & ops updates.
AI Summary
Avidity Biosciences, Inc. filed its quarterly report for the period ending March 31, 2025. The company reported its financial results and provided updates on its business operations. Specific financial figures and operational details for the first quarter of 2025 are detailed within the filing.
Why It Matters
This filing provides investors with the latest financial health and operational progress of Avidity Biosciences, crucial for understanding its current standing and future prospects in the pharmaceutical sector.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Avidity Biosciences faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Players & Entities
- Avidity Biosciences, Inc. (company) — Filer of the 10-Q report
- 20250331 (date) — End of the reporting period
- 20250508 (date) — Filing date of the report
- SAN DIEGO, CA (location) — Company's business and mailing address
FAQ
What is the reporting period for this 10-Q filing?
The reporting period for this 10-Q filing is March 31, 2025.
When was this 10-Q filing submitted to the SEC?
This 10-Q filing was submitted on May 8, 2025.
What is the primary business of Avidity Biosciences, Inc. according to the filing?
Avidity Biosciences, Inc. is in the Pharmaceutical Preparations industry (SIC code 2834).
What is the company's fiscal year end?
The company's fiscal year ends on December 31.
What were the previous names of Avidity Biosciences, Inc.?
The company was formerly known as Avidity NanoMedicines LLC and Avidity Biosciences LLC.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 8, 2025 regarding Avidity Biosciences, Inc..